For the quarter ending 2026-03-31, SBRA had $45,371K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 40,813 | 27,147 | 128,363 | - |
| Depreciation and amortization | 53,131 | 51,405 | 48,511 | 87,080 |
| Other non-cash items | - | 0 | 0 | -17,190 |
| Non-cash rental and related revenues | -1,599 | -1,840 | 7,151 | -6,331 |
| Non-cash interest income | 0 | 0 | 0 | -7 |
| Non-cash interest expense | 2,368 | 2,362 | 2,153 | 3,455 |
| Stock-based compensation expense | 3,098 | 3,070 | 2,875 | 5,415 |
| Loss on extinguishment of debt | - | 0 | -1,154 | - |
| Recovery of loan losses | -213 | -407 | -240 | -400 |
| Net loss (gain) on sales of real estate | - | -9,063 | -4,430 | 9,974 |
| Impairment of real estate | 440 | 648 | 2,571 | 4,103 |
| Income from unconsolidated joint ventures | 1,912 | 1,652 | 1,226 | 1,050 |
| Net income | - | - | - | 105,846 |
| Distributions of earnings from unconsolidated joint ventures | 1,657 | 1,896 | 1,895 | 4,022 |
| Accounts receivable, prepaid expenses and other assets, net | 1,534 | 2,320 | 2,262 | 6,867 |
| Accounts payable and accrued liabilities | 2,113 | -1,945 | 10,435 | -6,894 |
| Net cash provided by operating activities | 98,362 | 87,427 | 99,964 | 161,222 |
| Acquisition of real estate and lease intangibles | 96,101 | 151,370 | 240,426 | 61,137 |
| Origination and fundings of loans receivable | 0 | 1,200 | 2,600 | 3,110 |
| Net proceeds from the sales of real estate | - | 45,550 | 39,514 | 3,573 |
| Origination and fundings of preferred equity investments | 15 | 0 | 0 | 9 |
| Net proceeds from sales-type lease | - | 0 | - | - |
| Additions to real estate | 11,851 | 17,338 | 10,614 | 13,569 |
| Proceeds from net investment hedges | - | 0 | 0 | 4,462 |
| Escrow deposits for potential investments | -70 | - | 500 | - |
| Repayments of loans receivable | 1,944 | 5,229 | 8,394 | 7,048 |
| Repayments of preferred equity investments | -1,256 | -556 | -608 | -1,369 |
| Investment in unconsolidated joint ventures | 0 | 0 | 0 | 1,241 |
| Insurance proceeds | 107 | 322 | 229 | 1,038 |
| Distributions in excess of earnings from unconsolidated joint ventures | - | 1,205 | 5,557 | - |
| Net cash used in investing activities | -105,090 | -116,546 | -199,838 | -61,576 |
| Net borrowings from revolving credit facility | - | - | 119,661 | 55,144 |
| Net borrowings from (repayments of) revolving credit facility | 137,800 | 109,805 | - | - |
| Principal payments on senior unsecured notes | - | 0 | 500,000 | - |
| Proceeds from term loans | - | 0 | 500,000 | - |
| Principal payments on secured debt | 531 | 527 | 524 | 1,038 |
| Payments of deferred financing costs | 92 | 0 | 4,325 | 80 |
| Payments related to extinguishment of debt | - | 0 | 2,884 | - |
| Contributions from noncontrolling interests | 4 | 6 | 2,040 | - |
| Payment of contingent consideration | 1,178 | 0 | - | - |
| Issuance of common stock, net | -8,247 | 39,431 | 164,139 | 24,211 |
| Dividends paid on common stock | 75,657 | 74,805 | 71,938 | 142,754 |
| Net cash provided by (used in) financing activities | 52,099 | -100,895 | 206,169 | -64,517 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 45,371 | -130,014 | 106,295 | 35,129 |
| Effect of foreign currency translation on cash, cash equivalents and restricted cash | -60 | 636 | -245 | - |
| Cash, cash equivalents and restricted cash, beginning of period | 78,140 | 207,518 | 66,339 | - |
| Cash, cash equivalents and restricted cash, end of period | 123,451 | 78,140 | 207,518 | - |
Sabra Health Care REIT, Inc. (SBRA)
Sabra Health Care REIT, Inc. (SBRA)